Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H37ClN4O.2ClH.H2O |
Molecular Weight | 572.01 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.Cl.NC(=O)C1(CCN(CCCN2C3=CC=CC=C3CCC4=C2C=C(Cl)C=C4)CC1)N5CCCCC5
InChI
InChIKey=SWCNPPOGIXOVAZ-UHFFFAOYSA-N
InChI=1S/C28H37ClN4O.2ClH.H2O/c29-24-12-11-23-10-9-22-7-2-3-8-25(22)33(26(23)21-24)18-6-15-31-19-13-28(14-20-31,27(30)34)32-16-4-1-5-17-32;;;/h2-3,7-8,11-12,21H,1,4-6,9-10,13-20H2,(H2,30,34);2*1H;1H2
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C28H37ClN4O |
Molecular Weight | 481.073 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://medical.mt-pharma.co.jp/di/file/if/f_clo.pdfCurator's Comment: description was created based on several sources, including:
http://www.kegg.jp/medicus-bin/japic_med_product?id=00048317-003 | http://en.pharmacodia.com/web/drug/1_10640.html
Sources: https://medical.mt-pharma.co.jp/di/file/if/f_clo.pdf
Curator's Comment: description was created based on several sources, including:
http://www.kegg.jp/medicus-bin/japic_med_product?id=00048317-003 | http://en.pharmacodia.com/web/drug/1_10640.html
Clocapramine is a chlorinated derivative of carpipramine. The hydrochloride has been given orally in the treatment of schizophrenia. Clocapramine is an antagonist of the Dopamine D2 and Serotonine (5-HT2) receptors. It has been implicated in at least one strange death, including a suicide. It augments the paroxetine in the panic disorder treatment.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7766287 |
13.0 nM [Ki] | ||
Target ID: CHEMBL322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8786644 |
1.9 nM [Ki] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8786644 |
1.5 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLOFEKTON Approved UseClofekton 10% is indicated for the treatment of schizophrenia. Launch Date1974 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8786644
Various concentrations of clocapramine was applied to NCB20 cells and reward currents were recorded. The cells were voltage-clamped at -60 mV. The compositions of internal and external solutions were both normal. Concentration-response curves for each compound were obtained from 6 to 10 cell. The Hill coefficients of clocapramine was 0.79. The Ka values for these compounds was 1.1 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:35:27 GMT 2023
by
admin
on
Fri Dec 15 17:35:27 GMT 2023
|
Record UNII |
9NLU6H3LRD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB01349MIG
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | |||
|
60789-62-0
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | |||
|
5282503
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | |||
|
300000022031
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | |||
|
9NLU6H3LRD
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | |||
|
m3631
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT002792
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104103
Created by
admin on Fri Dec 15 17:35:27 GMT 2023 , Edited by admin on Fri Dec 15 17:35:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |